SocialPicks Sentiment:
** v.s.
other stocks
|
This Quarter's Sentiment:
|
|
|
MNKD Analysis & Videos »
MNKD: Bull or Bear?
MannKind: Speculation on inhaled insulin
MNKD
-18.56%
in
129 days
Filed under: Newsletters, Stocks to Buy "In looking for a highly speculative stock for our portfolio, I have settled on MannKind Corp. (NASDAQ: MNKD), a company that is developing an inhaled insulin product," says Nate Pile. In his growth-oriented Nate's Notes, the advisor cautions, "I believe we are looking at a situation in which we will either lose most of our money, or triple (or better) our investment in a fairly short period of time." <>"In a nutshell, the company's near-term fate hinges upon AFRESA, a novel, ultra rapid acting mealtime insulin therapy being studied for use in adult patien...
|
Updated Clinical Trial and FDA Decision Calendars
MNKD
|
|
|
+92.96%
in
240 days
<> <> Updated Clinical Trial and FDA Calendars
Below is a summary of updates to the www.BioMedReports.co <wbr> </wbr> m database of 243 entries included in the FDA and Clinical Trial Calendars.
http://biomedreports <wbr> </wbr> .com/fda-calendar.ht <wbr> </wbr> ml
The FDA Calendar includes companies with pending new drug, biological agent, or medical device new product decisions at the FDA sorted by their PDUFA deadline dates. The entries are updated on a daily basis as new information becomes available with a total of 104 entries through today. The FDA Calend...
|
No Relief in Sight for MannKind
MNKD
-137.55%
in
488 days
We believe the Food and Drug Administration (FDA) will decide to err on the side of caution and request MannKind for additional clinical information. This part was added on experimental basis to see the effect. This part was added on experimental basis to see the effect. This part was added on experimental basis to see the effect. This part was added on experimental basis to see the effect. This part was added on experimental basis to see the effect. This part was added on experimental basis to see the effect. This part was added on experimental basis to see the effect. This part was added ...
|
Mannkind: Overlooked Biotech With Excellent Prospects (Part VI)
MNKD
+126.12%
in
507 days
Part VI: Conclusion – Summary, valuation, and risks This is the final part of my six-part series on Mannkind (MNKD). Be sure to see Part 1, Part 2, Part 3, Part 4, and Part 5, if you have not done so already. I will now summarize the key points and get into valuation. <>Mannkind is a development-stage biotech company, which is close to filing for FDA approval for its first product, Technosphere Insulin. (They have some other products in their pipeline, all in early stages, but they’re not so important. See Part 5 for more discussion about them.) Technosphere Insulin is an inhaled form of ...
|
Mannkind: Overlooked Biotech With Excellent Prospects (Part V)
MNKD
+1.75%
in
3 days
(closed on 06/22/08)
Part V: Mannkind’s (MNKD) pipeline potential <>This is part 5 of my six-part series covering Mannkind. In Part 1, I explained why Technosphere Insulin, Mannkind’s upcoming inhaled insulin, is a breakthrough product with the potential to significantly improve diabetes treatment. In Part 2, I explained why Pfizer’s (PFE) lung cancer scare with Exubera (a competing inhaled insulin) was just that – a scare. In Part 3, I highlighted some of the differences between Pfizer’s failed Exubera and Mannkind’s Technosphere Insulin. In Part 4, I discussed Mannkind’s partnership opportun...
|
Mannkind: Overlooked Biotech With Excellent Prospects (Part IV)
MNKD
+1.06%
in
2 days
(closed on 06/19/08)
Part IV: Mannkind’s (MNKD) partnership opportunities for Technosphere Insulin <>This is Part 4 of my six-part series covering Mannkind. In Part 1, I explained why Technosphere Insulin, Mannkind’s upcoming inhaled insulin, is a breakthrough product with the potential to significantly improve diabetes treatment. In Part 2, I explained why Pfizer’s (PFE) lung cancer scare with Exubera (a competing inhaled insulin) was just that – a scare. In Part 3, I highlighted some of the differences between Pfizer’s failed Exubera and Mannkind’s Technosphere Insulin. I am now going to discu...
|
Mannkind: Overlooked Biotech With Excellent Prospects (Part II)
MNKD
+8.76%
in
2 days
(closed on 06/13/08)
Part II: Pfizer’s (PFE) cancer announcement and its irrelevance to Mannkind’s (MNKD) future <>As I explained in detail in Part 1 of this series (see here if you missed it), Mannkind has a potential home run with Technosphere Insulin, their upcoming drug for diabetes. Technosphere Insulin is an inhaled insulin which is more convenient for patients and, more importantly, has significant medical advantages. It has lower rates of hypoglycemia (dangerously low levels of blood sugar) than conventional injected insulin, and promotes weight loss instead of the weight gain common with conv...
|
Mannkind: Overlooked Biotech With Excellent Prospects (Part I)
MNKD
-16.05%
in
3 days
(closed on 06/11/08)
Part I: Inhaled Insulin, the wave of the future This is the first part of a six-part series on Mannkind – an overlooked, unfollowed company whose stock has dropped rapidly to around $3 a share. After an extensive analysis, I believe we have here an uncommon opportunity to profit from the market’s ignorance. <>Mannkind is a biotech company which is close to bringing to market their first product, inhaled insulin for diabetes (they expect to file for approval by the end of this year). Before delving into the details of their inhaled insulin and their drug pipeline, I will summarize in short ...
|
People Bullish on MNKD
People Bearish on MNKD
|
ROCK-STAR INVESTORS
|
|
POPULAR STOCKS
|
|
TODAY'S HEADLINES
|
|
TODAY'S TOP PICKS
|
|
|
| StreetInsider.com on MNKD |
More Resources
|
About MannKind Corp.
- Answers.com
